XORTX Announces Change of Effective Date of Share Consolidation
Rhea-AI Summary
XORTX (NASDAQ: XRTX) announced a change to the effective date of its previously disclosed share consolidation from March 27, 2026 to April 6, 2026. The consolidation remains a 1-for-5 share consolidation and is still subject to required approvals from the TSX Venture Exchange and Nasdaq Stock Exchange.
The company attributed the change to timing considerations and confirmed the consolidation will only proceed after receipt of all required exchange approvals.
Positive
- Share consolidation ratio confirmed at 1-for-5
- New effective date set for April 6, 2026
Negative
- Implementation delayed from March 27, 2026 to April 6, 2026
- Consolidation remains conditional on TSXV and Nasdaq approvals
News Market Reaction – XRTX
In the Mar 27 session, XRTX gained 9.88%, reflecting a notable positive market reaction. Argus tracked a trough of -15.9% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| 2026-03-24 | Share consolidation approval | Neutral | -0.8% | Shareholders approved up to 5-for-1 share consolidation to aid Nasdaq compliance. |
| 2026-03-18 | Director nominees, financing | Positive | +6.5% | New director nominees proposed as condition for a significant financing transaction. |
| 2026-03-05 | Meeting materials mailed | Neutral | +7.8% | Filed and mailed materials outlining agenda including up to 5-for-1 share consolidation. |
| 2026-02-04 | Acquisition update | Positive | -17.7% | Extended deadline to close VB4-P5 renal anti-fibrotic program acquisition to March 31, 2026. |
| 2025-12-31 | Research, corporate update | Positive | +1.4% | Highlighted new gout genetic research and confirmed a US$1.1M financing closing. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent governance and consolidation announcements often saw aligned price moves, with one notable selloff on an acquisition update.
Over recent months, XORTX news has focused on governance, capital structure, and pipeline positioning. On Mar 24, 2026, shareholders approved a share consolidation of up to 5-for-1 to support Nasdaq bid-price compliance. Earlier in March, the company mailed meeting materials and proposed director changes tied to a significant financing, with mixed price reactions. A February update on acquiring the VB4‑P5 renal anti-fibrotic program drew a sharper negative move. Today’s adjustment to the consolidation effective date fits into this broader restructuring narrative.
Key Terms
AI-generated analysis. How Rhea-AI works. Not financial advice.
CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, further to its news release of March 25, 2026, the Company has delayed the implementation of its share consolidation on the basis of one (1) new common share for every five (5) old common shares (the “Consolidation”) from March 27, 2026 to April 6, 2026, and remains subject to the receipt of all required approvals of the TSX Venture Exchange and Nasdaq Stock Exchange.
About XORTX Therapeutics Inc.
XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead program XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases. Additional information on XORTX is available at www.xortx.com.
For more information, please contact:
| Allen Davidoff, CEO | Nick Rigopulos, Director of Communications |
| adavidoff@xortx.com | nick@alpineequityadv.com |
| +1 403 455 7727 | +1 617 901 0785 |
Forward Looking Statements
This press release contains express or implied forward-looking statements pursuant to applicable securities laws. These forward-looking statements include, but are not limited to, the Company's beliefs, plans, goals, objectives, expectations, assumptions, estimates, intentions, future performance, other statements that are not historical facts and statements identified by words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates” or words of similar meaning. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks, uncertainties, and other factors include, but are not limited to, regulatory approvals, such as the TSXV; the ability to complete the Consolidation; the success and timing of our preclinical studies and clinical trials; the performance of third-party manufacturers and contract research organizations; our plans to develop and commercialize our product candidates; our plans to advance research in other kidney disease applications; and, our ability to obtain and maintain intellectual property protection for our product candidates. Except as otherwise required by applicable law and stock exchange rules, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading “Risk Factors” in XORTX’s Annual Report on Form 20-F filed with the SEC, which is available on the SEC's website, www.sec.gov (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on www.sedarplus.ca.
